---
title: "SMMT.US (SMMT.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/SMMT.US/news.md"
symbol: "SMMT.US"
name: "SMMT.US"
parent: "https://longbridge.com/en/quote/SMMT.US.md"
datetime: "2026-05-20T06:46:13.792Z"
locales:
  - [en](https://longbridge.com/en/quote/SMMT.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/SMMT.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/SMMT.US/news.md)
---

# SMMT.US (SMMT.US) — Related News

### [Notable Tuesday Option Activity: CAVA, AGYS, SMMT](https://longbridge.com/en/news/286957282.md)
*2026-05-19T19:25:23.000Z*
> Today, notable options trading activity was observed in CAVA Group Inc (CAVA) with 26,409 contracts traded, representing

### [3 Best Stocks to Buy This Week, According to Analysts – May 18-May 22](https://longbridge.com/en/news/286816644.md)
*2026-05-18T20:12:08.000Z*
> Analysts recommend three stocks for this week: Zeta Global (ZETA), Boston Scientific (BSX), and Summit Therapeutics (SMM

### [Summit Therapeutics (SMMT) Is Down 20.1% After Q1 2026 Net Loss Widens Sharply](https://longbridge.com/en/news/285869451.md)
*2026-05-11T02:14:20.000Z*
> Summit Therapeutics Inc. reported a significant widening of its net loss to $189.42 million for Q1 2026, compared to $62

### [Tyler Van Buren Reiterates Buy on Summit Therapeutics, Citing Stable Long-Term Sales Outlook and Attractive Risk/Reward Despite Higher Future OpEx](https://longbridge.com/en/news/285420620.md)
*2026-05-06T17:25:23.000Z*
> TD Cowen analyst Tyler Van Buren has reiterated a Buy rating on Summit Therapeutics (SMMT) due to a stable long-term sal

### [A Look At Summit Therapeutics (SMMT) Valuation After Trial Update And Going Concern Warning](https://longbridge.com/en/news/285084528.md)
*2026-05-04T14:05:38.000Z*
> Summit Therapeutics (SMMT) faces significant scrutiny after its stock plummeted due to the continuation of its Phase III

### [Summit Therapeutics (SMMT) Is Down 27.0% After HARMONi-6 OS Plenary, BLA Progress And Wider Losses - Has The Bull Case Changed?](https://longbridge.com/en/news/284977345.md)
*2026-05-02T22:07:05.000Z*
> Summit Therapeutics Inc. reported a widening net loss of $189.4 million for Q1 2026, with a loss per share of $0.24. The

### [Summit Therapeutics (SMMT) Receives a Rating Update from a Top Analyst](https://longbridge.com/en/news/284973425.md)
*2026-05-02T17:05:17.000Z*
> Summit Therapeutics (SMMT) received a Hold rating from analyst Faisal Khurshid of Jefferies, with a price target of $17.

### [Summit Therapeutics (NASDAQ:SMMT) Raised to "Sell" at Wall Street Zen](https://longbridge.com/en/news/284958038.md)
*2026-05-02T06:50:47.000Z*
> Wall Street Zen upgraded Summit Therapeutics (NASDAQ:SMMT) from a "strong sell" to a "sell" rating. Other analysts have 

### [Summit Therapeutics Flags Significant Going-Concern Risk Amid Cash Shortfall and Uncertain Financing](https://longbridge.com/en/news/284957798.md)
*2026-05-02T06:00:56.000Z*
> Summit Therapeutics PLC (SMMT) has flagged a significant going-concern risk due to insufficient cash and short-term inve

### [](https://longbridge.com/en/news/284944635.md)
*2026-05-01T22:02:13.000Z*
> The Nasdaq Biotechnology Index fell 1.09%. Among its constituents, Summit Therapeutics Plc dropped 24.91%, Syndax Pharma